Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (1y) (2021 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 28.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -57.58% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -59.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.86% |
| Mar 31, 2026 | -32.50% |
| Dec 31, 2025 | 146.45% |
| Sep 30, 2025 | 4,089.72% |
| Jun 30, 2025 | 2,418.83% |
| Mar 31, 2025 | 3,020.72% |
| Dec 31, 2024 | 516.36% |
| Sep 30, 2024 | -93.85% |
| Jun 30, 2024 | 62.01% |
| Mar 31, 2024 | -40.52% |
| Dec 31, 2023 | 27.50% |
| Sep 30, 2023 | 157.03% |
| Jun 30, 2023 | -94.09% |
| Mar 31, 2023 | -89.19% |
| Dec 31, 2022 | -82.36% |
| Sep 30, 2022 | -87.11% |
| Jun 30, 2022 | -31.22% |
| Mar 31, 2022 | 280.98% |
| Dec 31, 2021 | 192.04% |
| Sep 30, 2021 | 277,274.75% |